Kingstown Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Kingstown Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$18K	Hold	300,000	–	–	0.06%	22
2022 Q2	$27K	Hold	300,000	–	–	0.04%	39
2022 Q1	$72K	Hold	300,000	–	–	0.11%	42
2021 Q4	$198K	Hold	300,000	–	–	0.25%	43
2021 Q3	$198K	Hold	300,000	–	–	0.2%	54
2021 Q2	$258K	Buy	300,000 +50,000	+20%	+$34.8K	0.15%	77
2021 Q1	$150K	Buy	+250,000	New	+$176K	0.05%	82

Other funds holding BIOTW

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

ACM

Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return

Kingstown Capital Management's BIOTW Position: Q3 2022 in Review

Kingstown Capital Management held its Biotech Acquisition Company Warrant (BIOTW) position steady in Q3 2022 at 300,000 shares worth $18K. The position accounts for 0.06% of the portfolio, ranked #22.

Kingstown Capital Management first reported a position in BIOTW in Q1 2021 and has held it in 7 quarters since. The position peaked at $258K in Q2 2021. 51 funds tracked by Wall St. Rank hold BIOTW as of Q3 2022.

Kingstown Capital Management held 300,000 shares of Biotech Acquisition Company Warrant worth $18K as of Q3 2022.
Kingstown Capital Management left its Biotech Acquisition Company Warrant share count unchanged in Q3 2022.
Biotech Acquisition Company Warrant made up 0.06% of Kingstown Capital Management's portfolio in Q3 2022, its #22 holding.
Kingstown Capital Management first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and has held it in 7 quarters since.
Kingstown Capital Management's Biotech Acquisition Company Warrant position peaked at $258K in Q2 2021.
51 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q3 2022.

Based on Kingstown Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.